Milestone Scientific launched the CompuFlo® Epidural System at Advanced Spine and Pain Management, enhancing safety and efficiency in epidural procedures.
Quiver AI Summary
Milestone Scientific Inc., a developer of computerized drug delivery systems, has announced the commercial launch of its CompuFlo Epidural System at Advanced Spine and Pain Management, LLC, following a successful pilot program with Dr. Varinder Dhillon. This innovative system, which utilizes patented Dynamic Pressure Sensing Technology, enhances patient safety and procedural efficiency by providing real-time feedback on needle placement during epidural procedures. The recent Medicare price assignment has also contributed to the increasing adoption of the CompuFlo system across pain management clinics. Dr. Dhillon praised the technology for improving the quality of care, while Milestone's CEO highlighted the growing traction of the system in the healthcare community.
Potential Positives
- The commercial rollout of the CompuFlo® Epidural System at a premier clinic highlights successful market entry and potential for growth.
- Successful pilot program feedback from a reputable physician validates the clinical benefits of the CompuFlo® Epidural System, enhancing credibility.
- Increasing adoption of the CompuFlo® Epidural System following Medicare price assignment signifies its perceived clinical and economic advantages.
- The technology enhances patient safety and procedural efficiency, addressing key concerns in medical practices.
Potential Negatives
FAQ
What is the CompuFlo® Epidural System?
The CompuFlo® Epidural System is an advanced injection technology that provides painless and precise epidural injections using real-time feedback for accurate needle placement.
Where is the CompuFlo® Epidural System being rolled out?
The CompuFlo® Epidural System has been commercially rolled out at Advanced Spine and Pain Management in Montvale, New Jersey.
What are the benefits of the CompuFlo® Epidural System?
This system enhances patient safety, improves procedural efficiency, and reduces complications compared to traditional epidural injection techniques.
Who validated the clinical benefits of the CompuFlo® Epidural System?
Dr. Varinder Dhillon provided expertise and feedback that validated the clinical benefits during the successful pilot program.
What does Dynamic Pressure Sensing Technology® do?
The Dynamic Pressure Sensing Technology® allows real-time monitoring of pressure, ensuring precise needle placement in epidural procedures.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MLSS Insider Trading Activity
$MLSS insiders have traded $MLSS stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $MLSS stock by insiders over the last 6 months:
- LEONARD OSSER has made 0 purchases and 2 sales selling 249,897 shares for an estimated $235,242.
- MICHAEL MCGEEHAN has made 0 purchases and 4 sales selling 23,009 shares for an estimated $18,541.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MLSS Hedge Fund Activity
We have seen 13 institutional investors add shares of $MLSS stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- Y-INTERCEPT (HONG KONG) LTD added 52,368 shares (+inf%) to their portfolio in Q3 2024, for an estimated $47,681
- KESTRA ADVISORY SERVICES, LLC added 41,100 shares (+inf%) to their portfolio in Q3 2024, for an estimated $37,421
- VANGUARD GROUP INC added 34,556 shares (+1.6%) to their portfolio in Q3 2024, for an estimated $31,463
- GEODE CAPITAL MANAGEMENT, LLC added 31,572 shares (+6.4%) to their portfolio in Q3 2024, for an estimated $28,746
- CITADEL ADVISORS LLC removed 31,169 shares (-57.4%) from their portfolio in Q3 2024, for an estimated $28,379
- RADNOR CAPITAL MANAGEMENT, LLC added 31,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $29,760
- WELLS FARGO & COMPANY/MN removed 30,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $27,315
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ROSELAND, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the commercial rollout of its CompuFlo® Epidural System at Advanced Spine and Pain Management, LLC, a premier pain management clinic. This rollout follows a successful pilot program conducted with Dr. Varinder Dhillon, whose expertise and feedback validate the clinical benefits of the CompuFlo® Epidural System in enhancing patient safety and procedural efficiency.
Advanced Spine and Pain Management operates out of SurgiCore Montvale, one of 12 SurgiCore centers located in the New York/New Jersey metropolitan area, highlighting the opportunity for further expansion within the SurgiCore network. In addition, the Company reports increasing adoption of the CompuFlo® Epidural System following the previously announced Medicare price assignment, reflecting its clinical and economic benefits.
The CompuFlo® Epidural System, utilizing Milestone Scientific’s patented Dynamic Pressure Sensing Technology®, provides real-time feedback to confirm accurate needle placement during epidural procedures. This innovative technology significantly reduces the risk of complications associated with traditional techniques, enhancing both patient safety and procedural efficiency.
Dr. Dhillon commented, "The CompuFlo® Epidural System has transformed the way we approach epidural procedures. The technology’s precision and reliability enable us to deliver safer and more comfortable care to our patients, while also improving procedural efficiency. I am thrilled integrate it into my workflow at Advanced Spine and Pain Management, and am confident it will continue to deliver outstanding results."
Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, stated, "The adoption of the CompuFlo® Epidural System by Dr. Dhillon at Advanced Spine and Pain Management illustrates our traction within the healthcare community. With the recent Medicare price assignment, we are witnessing increased adoption of the CompuFlo Epidural System across pain management clinics and other healthcare facilities nationwide."
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology
®
instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the
MLSS brand video
or visit
milestonescientific.com
.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023 . The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email:
[email protected]
Tel: 212-671-1020